Kymera Therapeutics (KYMR) announced that the FDA has granted fast track designation to KT-621, its oral STAT6 degrader, for the treatment of moderate to severe eosinophilic asthma. KT-621 is currently being studied in two global Phase 2b studies, including for the treatment of moderate to severe eosinophilic asthma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Reaffirming Buy: Kymera’s Protein Degradation Platform and KT-621 Pipeline Advance Underpin Long-Term Value
- Kymera Therapeutics announces Gilead option exercise to license KT-200
- Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
- Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
- Kymera Therapeutics assumed with a Buy at Jefferies